Bruno Duarte

Hematologist in Brazil with a primary interest in myeloid malignancies. Opinions are my own.

[SBTMO @SBTMO]

A Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea lamenta o falecimento do Dr. Marcos Paulo Colella e presta solidariedade aos familiares, amigos e colegas, reconhecendo seu importante legado para a Hematologia brasileira.

[Alex Rampotas @ARampotas]

1/ 🧵 So delighted to share our new paper, out today in Science Translational Medicine @ScienceTM. We built a CAR-T cell therapy that selectively depletes the disease-driving mutant calreticulin (mutCALR) cells in myelofibrosis — while sparing healthy blood stem cells👇

https://t.co/zfwYYSqT9h

[Bruno Duarte @bklduarte]

@doctorpemm @r_sazevedo @TapKadia @garciamanero @NitinJainMD @Daver_Leukemia @AP_Singh_MD @wdmarrero @mtmdphd @HannahGoulart @JKekedjian @AlexBataller Congrats @r_sazevedo. Well deserved!

[Bruno Duarte @bklduarte]

And making it fixed-duration! No one is progressing beyond 6 mo. How long will CR, MRDneg patients be taking this for?

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

INCREDIBLE ❤️

This will make patients with myeloma really happy ☺️

Next step, making sure everyone who needs these therapies can actually get them 🙏🏽

#ASH25 @NEJM
https://t.co/Eut8C9ztNK

[Bruno Duarte @bklduarte]

@Papa_Heme Molecular MRD?

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

You can use this QR code or link
https://t.co/ftLyvtrtsO to access our recent paper on classification of myeloid neoplasms in @BCD_AACR for free for the duration of @SocietyofHemOnc next week. 🩸
#hemepath #soho2025 #leusm

[Shoichiro Takeishi @ShoTakeishi]

Excited to share our latest work @Nature! We show that the total number of hematopoietic stem cells (HSCs) in the body is restricted, challenging the classical model that HSC numbers are determined locally by the niche and introducing a new paradigm. (1/9)
https://t.co/kvFqNQ8Nxb

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Congrats @r_sazevedo on her paper, out today in @BrJHaem She screened CD123 expression in AML to assess CD123 correlation w/ genotype. Timely as more anti-CD123 targeted therapies become available for AML pts #hemepath #LeuSM
https://t.co/3LllNQDlyP

[Stefano Luminari, MD @StefanoLuminari]

https://t.co/Z1T6ZysKbC

[Klaus Metzeler has left Twiitter 🇺🇦 @KlausMetzelerMD]

Clonal hematopoiesis (CH) is common in older persons without hematologic disease - but what about those who previously had acute myeloid leukemia, and survived the disease? @ScimonkM looked at CH in 373 AML long-term survivors: https://t.co/K0dH8mNs2z (1/10)

[Fadi Haddad, MD @FadiHaddad_MD]

📢 Out in @NEJMEvidence

👫N=1132 pts; age 18-60
🔹ND #AML
🔹Consolidation with IDAC vs HIDAC
🔹5-yr OS = 59% vs 58%
🔹Lower incidence of myelosuppressio & AEs with IDAC
➡️ IDAC non inferior to HIDAC

#leusm @OncoAlert

https://t.co/mtooZ8M270

[Bruno Duarte @bklduarte]

@DavidSteensma Thanks!

[Bruno Duarte @bklduarte]

@DavidSteensma Thanks for all the helpful insights Dr Steensma. Do you think we should target specific mutations (i.e.: splicing) or a common metabolic weakness (if any)? Also, do you think this result questions the AML/MDS proposed by the ICC (VIALE-A improves OS in pts with > 20% blasts)

[Wellington Fernandes @wellingtonhemat]

The impact of clinical features on survival and relapse of patients diagnosed with T-cell acute lymphoblastic leukemia – a multicenter cohort study - 🇧🇷💚 https://t.co/GpX5z5ukwV

[Javier Bolaños Meade, MD @GvHD_Meade]

#BMTCTN1703 #PTCyRules

[Eirini Papapetrou, MD, PhD @PapapetrouMDPhD]

🎉Excited to present our latest work out today @Nature 1.What gives a leukemia its phenotype – the oncogenic driver or the differentiation stage of the cell-of-origin? 2.Why do RAS mutations always happen late in AML? 3.Who will relapse after VEN? https://t.co/JAHNAw33wH

[ASH @ASH_hematology]

ASH is redefining ANC reference ranges based on Duffy status. No patient should face uncertainty in their medical treatment because of their genetics. #ASHDEI #HealthEquity

[Michael Rauh @QMyPath]

CHIP: a novel risk factor for AKI @NatureMedicine. Large 🇨🇦/🇺🇸 collab driven primarily @queensu & @VanderbiltU @AlexBickMDPhD led by incredible @DrFlashHeart. Our part graciously supported by @tmedQueens @QueensPathology @QueensUHealth with funding from @PSIFoundation @CIHR_IRSC

[Bruno Duarte @bklduarte]

@QMyPath @NatureMedicine @queensu @VanderbiltU @AlexBickMDPhD @DrFlashHeart @tmedQueens @QueensPathology @QueensUHealth @PSIFoundation @CIHR_IRSC Congrats!!

[Bruno Duarte @bklduarte]

@QMyPath @emmamgroarke @BloodAdvances @genome_gov Very nice to see our initial report reproduced in a larger cohort! Still intrigued about which is the mechanistic role of NFE2 mutations in RUNX1 FPDMM progression to AML/MDS.